Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent Non-Hodgkin Lymphomas

T

Tainan Municipal Hospital

Status

Withdrawn

Conditions

Hepatitis c

Treatments

Drug: Daclatasvir+ Asunaprevir

Study type

Observational

Funder types

Other

Identifiers

NCT02762448
AI447-122

Details and patient eligibility

About

Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent non-Hodgkin Lymphomas Patients Using Daclatasvir and Asunaprevir: A Pilot Study

Full description

Prospectively collect cases with NHL (n=10), having HCV genotype 1b related NHL, who will be treated with ASV (200 mg twice daily) + DCV(60 mg once daily) for 24 weeks The patients will be observed and followed to determine whether there is regression of NHL after antiviral treatment. Conventional chemotherapy should be initiated shortly in cases without regression.

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Men and women
  • 18 to 70 years of age
  • Who had chronic HCV genotype 1b infection
  • An HCV RNA level of 105 IU per milliliter or higher
  • Being diagnosed to be low grade B cell non-Hodgkin lymphoma

Exclusion criteria

  • Patients with hepatitis B virus infection,
  • Other liver diseases
  • HIV infection,
  • Pre-existing HCV variants in the NS5A domain included Q30R, L31 M/V, and Y93C/N
  • Evidence of cirrhosis, as documented by means of either liver biopsy or assessment of imaging results.

Trial design

0 participants in 1 patient group

Daclatasvir + Asunaprevir
Description:
Prospectively collect cases with NHL (n=10), having HCV genotype 1b related NHL, who will be treated with ASV (200 mg twice daily) + DCV(60 mg once daily) for 24 weeks .
Treatment:
Drug: Daclatasvir+ Asunaprevir

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems